Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The influence of apolipoprotein E4 on microglial activity in cervical spondylotic myelopathy

FY 2018-19

Summary
Cervical spondylotic myelopathy (CSM) is a devastating neurological condition resulting from the degeneration of spinal structures and the subsequent compression of the spinal cord. CSM is the most common cause of spinal cord dysfunction among adults (>55 years), and can result in severe sensory and motor deficits. Individuals carrying the apolipoprotein E4 (ApoE4) allele have a 77.8% greater risk of developing CSM, and have worse neurological outcomes following surgical treatment. While the role of ApoE4 in CSM pathology is currently unknown, recent evidence suggests that ApoE acts as a ligand for a crucial microglial receptor complex: Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) and DNAX-activating protein 12 (DAP12). Microglia are the innate immune cells of the central nervous system, and inflammatory activation of microglia results in the release of nitric oxide, cytokines, and proteases that can lead to neurotoxicity. Given that activated microglia are known to participate in CSM spinal cord pathology, I hypothesize that the ApoE4 isoform exacerbates CSM progression by promoting a pro-inflammatory microglial phenotype, specifically through interaction with the TREM2-DAP12 complex. The proposed study will focus on the following goals: (1) investigate the neuroinflammatory role ApoE4 and the TREM2-DAP12 complex has on CSM and (2) determine whether inhibition of TREM2-DAP12 signaling can mitigate the negative effect of ApoE4 on the complex in the diseased state. This proposal is the first to investigate the role of ApoE4 in CSM neuroinflammatory mechanisms and experimentally link ApoE4 expression to neurological outcomes in CSM. It will also provide proof-of-concept for a novel personalized medicine strategy to treat an at-risk ApoE4+ CSM population.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406564
Name
Desimone Alexa M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The influence of apolipoprotein E4 on microglial activity in cervical spondylotic myelopathy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apolipoprotein E4; Cervical Spondylotic Myelopathy; Microglia; Neuroinflammation; Personalized Medicine; Spinal Cord Disease; Therapeutic Approaches; Trem2-Dap12
Abstract
Cervical spondylotic myelopathy (CSM) is a devastating neurological condition resulting from the degeneration of spinal structures and the subsequent compression of the spinal cord. CSM is the most common cause of spinal cord dysfunction among adults (>55 years), and can result in severe sensory and motor deficits. Individuals carrying the apolipoprotein E4 (ApoE4) allele have a 77.8% greater risk of developing CSM, and have worse neurological outcomes following surgical treatment. While the role of ApoE4 in CSM pathology is currently unknown, recent evidence suggests that ApoE acts as a ligand for a crucial microglial receptor complex: Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) and DNAX-activating protein 12 (DAP12). Microglia are the innate immune cells of the central nervous system, and inflammatory activation of microglia results in the release of nitric oxide, cytokines, and proteases that can lead to neurotoxicity. Given that activated microglia are known to participate in CSM spinal cord pathology, I hypothesize that the ApoE4 isoform exacerbates CSM progression by promoting a pro-inflammatory microglial phenotype, specifically through interaction with the TREM2-DAP12 complex. The proposed study will focus on the following goals: (1) investigate the neuroinflammatory role ApoE4 and the TREM2-DAP12 complex has on CSM and (2) determine whether inhibition of TREM2-DAP12 signaling can mitigate the negative effect of ApoE4 on the complex in the diseased state. This proposal is the first to investigate the role of ApoE4 in CSM neuroinflammatory mechanisms and experimentally link ApoE4 expression to neurological outcomes in CSM. It will also provide proof-of-concept for a novel personalized medicine strategy to treat an at-risk ApoE4+ CSM population.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Desimone, Alexa M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~